Relmada Therapeutics, Inc. – Amendment No. 2 to Relmada Therapeutics, Inc. 2014 Stock Option and Equity Incentive Plan, as Amended (February 10th, 2017)
Pursuant to Section 9(a) of the 204 Stock Option and Equity Incentive Plan, as amended (the "Plan") of Relmada Therapeutics, Inc. (the "Company"), the Board of Directors of the Company has duly adopted a resolution, conditioned upon approval by the stockholders of the Company, approving this Amendment No. 2 to the Plan to increase the total number of shares of common stock, par value $.001 per share, of the Company (the "Common Stock") reserved and available for issuance under the Plan as follows:
Relmada Therapeutics, Inc. – Agreement (September 9th, 2016)
This Agreement ("Agreement") is entered into by and between Shreeram Agharkar ("Director" or "you") and Relmada Therapeutics, Inc. (the "Company"), and confirms the agreement that has been reached with you in connection with your resignation as a director of the Company.
Relmada Therapeutics, Inc. – Amendment (June 17th, 2016)
This Amendment to Offer Letter (the "Amendment") is dated as of the 16th day of June, 2016 (the "Effective Date") by and between RELMADA THERAPEUTICS, Inc. ("Relmada"), and Michael Becker ("Employee"). Capitalized terms use but not defined in this Amendment shall have the meaning ascribed in the Offer Letter (as herein defined).
Relmada Therapeutics, Inc. – Michael D. Becker 1478 Greenmeadows Road Yardley, PA 19067 Dear Mr. Becker, (May 13th, 2016)
On behalf of Relmada Therapeutics, Inc: (the "Company"), I am pleased to offer you the position of Senior Vice President of Finance and Corporate Development. Speaking for myself, as well as the other members of the management team, we are all impressed with your credentials and look forward to your future success in this position. The terms of your employment are set herein ("Employment Letter").
Actinium Pharmaceuticals, Inc. – Office Space License Agreement (March 11th, 2016)
Office Space License Agreement ("Agreement") dated March 10, 2016 and effective as of January 1, 2016, by and between RELMADA THERAPEUTICS, INC., a Nevada Corporation ("Relmada"), and ACTINIUM PHARMACEUTICALS, INC., a Delaware Corporation ("Client"), with respect to the license of the portion identified in Exhibit A (the "Client Area") of the portion of the 7th Floor of the office building located at 275 Madison Avenue, New York, New York ("Building"), upon and subject to the following terms, covenants and conditions.
Actinium Pharmaceuticals, Inc. – August 15, 2013 (October 28th, 2013)
Actinium Pharmaceuticals, Inc. – Share Exchange Agreement (August 22nd, 2013)
This SHARE EXCHANGE AGREEMENT ("Agreement"), dated as of August 22, 2013, is made by and among ACTINIUM PHARMACEUTICALS, INC., a corporation organized under the laws of Delaware (fka, Cactus Ventures, Inc.)(the "Acquiror"), ACTINIUM CORPORATION, a corporation organized under the laws of Delaware (fka, Actinium Pharmaceuticals, inc.)(the "Acquiree"), and each of the Persons listed on Schedule I hereto who are shareholders of the Acquiree (collectively, the "Acquiree Shareholders," and individually an "Acquiree Shareholder"). Each of the Acquiror, Acquiree and Acquiree Shareholders are referred to herein individually as a "Party" and collectively as the "Parties."